Table 1.

Characteristics of the overall study cohort.

Characteristics	Total = 170 n (%)
Female	58 (34.1%)
Age	59.3 ± 15.5
ICU	59 (34.7%)
Mechanical ventilation	44 (25.8%)
Hypotension at the time of COVID-19 diagnosis	22 (12.9%)
Vasopressor agents at the time of COVID-19 diagnosis	10 (5.9%)
High risk (MASCC score < 21) cases	71 (41.7%)
Low-risk neutropenia	99 (58.3%)
Antimicrobial therapy
BL/BLI including empirical monotherapy	61 (35.9%)
Carbapenem including empirical monotherapy	19 (11.2%)
Combination empirical therapy with glycopeptides	74 (43.5%)
Combination empirical therapy with quinolones	24 (14.1%)
Antifungal including empirical therapy	23 (13.5%)
Symptoms
Dyspnoea at the time of COVID-19 diagnosis	44 (25.8%)
Cough	95 (55.8%)
Diarrhoea	28 (16.5%)
Chest pain	28 (16.5%)
Headache	40 (23.5%)
Asymptomatic	16 (9.4%)

ICU intensive care unit, BL/BLI beta lactam beta lactamase inhibitor, COVID-19 Coronavirus disease 2019, MASCC Multinational Association of Supportive Care in Cancer.